RS : Full-year results (year ended 31 March 2023) Statement - Marketscreener.com

1 min to read

RS : Full-year results (year ended 31 March 2023) Statement – Marketscreener.com

Nasdaq Updates Listing Requirements

Throughout 2024, Nasdaq has been revising the procedures for companies dealing with low stock prices, with a focus on cutting...
S-4 – Akari Therapeutics Plc (0001541157) (Filer)

Filed: 2024-09-13 AccNo: 0001193125-24-218968 Size: 28 MB Source: S-4 - Akari Therapeutics Plc (0001541157) (Filer)
Looking Ahead to 2025: Navigating a Shifting D&O Insurance Landscape

In a market known for volatility, public company D&O (directors & officers) insurance has certainly lived up to its reputation...
S-1MEF – Bicara Therapeutics Inc. (0002023658) (Filer)

Filed: 2024-09-12 AccNo: 0001193125-24-218205 Size: 64 KB Source: S-1MEF - Bicara Therapeutics Inc. (0002023658) (Filer)
S-1/A – StandardAero, Inc. (0002025410) (Filer)

Filed: 2024-09-12 AccNo: 0001193125-24-218123 Size: 1 MB Source: S-1/A - StandardAero, Inc. (0002025410) (Filer)